Antimicrobial Resistance Diagnostics Market Size, Share & Trends Analysis Report By Technology (Microbiology Culture, Immunoassay, PCR, NGS), By Pathogen, By End User, By Region, And Segment Forecasts, 2022 - 2030

Report Overviews

The global antimicrobial resistance diagnostics market size was valued at USD 3.9 billion in 2021 and is expected to expand at a compound annual growth rate (CAGR) of 6.2% from 2022 to 2030. High disease burden from pathogens such as streptococcus pneumonia, MRSA, C. difficile infections, and others coupled with the surge in the incidence of Antimicrobial Resistance (AMR) infections are the major factors fueling the market growth. In addition, rising demand for technologically advanced diagnostic solutions to manage AMR and rising regulatory approvals of diagnostic products is also anticipated to support market growth. For instance, in September 2021, MeMed announced that its MeMed BV diagnostic test obtained 510(k) approval from the U.S. FDA. The test is used to distinguish bacterial and viral infections in point-of-care settings.

The rising threat of antimicrobial resistance is expected to facilitate market expansion. For instance, according to the CDC, about 2.8 million cases of AMR occur yearly in the U.S. Moreover, according to the United States Pharmacopeial Convention, AMR caused about 700,000 deaths globally every year. Moreover, the number can reach 10 million each year by 2050, if diagnosis and treatment of microbial infections are not managed properly.

Governments across the globe are striving to improve the quality of diagnostics for precise and point-of-care diagnosis. To develop novel and PoC diagnostic solutions, the Government of the U.K. has decided to incentivize R&D for new diagnostics in antimicrobial resistance. By 2024, the government aims to reduce R&D gaps, work with the global players to develop rapid & new generation diagnostic tests, and will promote research activities in AMR diagnostics. Moreover, in February 2020, the U.K. invested around USD 12 million in partnership with Nigeria to address the growing threat of drug-resistant infections. This partnership is aimed to upgrade laboratory equipment, improve public health surveillance systems, and training scientists and technicians.

In addition, the increase in regulatory approvals of technologically advanced and accurate diagnostic solutions is likely to cater to the market demand. For instance, in October 2021, Hologic, Inc launched a fully automated Novodiag molecular diagnostic solution of Mobidiag Oy in Europe for the on-demand testing of antimicrobial resistance and infectious diseases. The Novodiag system combines microarray and real-time PCR capabilities. This test can identify multiple pathogens from a single sample. Moreover, in October 2021, OpGen,Inc announced that it has received a 50(k) clearance from the U.S. FDA to market Acuitas AMR Gene Panel. It is capable to test a panel of 28 genetic antimicrobial resistance markers from a variety of pathogens and will help healthcare professionals to manage patients with resistant bacterial infections.

Furthermore, leading market players are collaborating to develop novel solutions for addressing the risk of developing drug-resistant infections. For instance, in July 2022, Boehringer Ingelheim, bioMérieux, and Evotec SE announced a joint venture to develop actionable diagnostics and the next generation of antibiotics to reduce the burden of antimicrobial resistance. Under this joint venture, bioMerieux will develop testing solutions for antibiotic resistance as 80% of the total investment is associated with the fight against AMR.

In January 2022, BD announced a collaboration with Pfizer Inc. and a global charitable foundation, Wellcome, for advancing the understanding of diagnostics and testing solutions in improving antimicrobial stewardship practice around the world. This collaboration is aimed to survey existing testing practices to understand both the gaps and benefits in antimicrobial resistance diagnostic procedures.

Technology Insights

The PCR segment dominated the market and accounted for the largest revenue share of 24.7% in 2021. Factors such as advancements in PCR technology, and high penetration of PCR technology due to high accuracy are the major factors contributing to the high segment share. In addition, increased adoption of PCR tests for HAIs such as MRSA and C. difficile is further fueling the segment expansion. Furthermore, the availability of robust and innovative product portfolios by leading market players is also expected to spur segment demand.

For instance, PathoKey MP UTI ID & AMR PCR Test developed by Vela Diagnostics is a real-time PCR solution for the detection of AMR genes and UTI pathogens. This test is capable of providing results for genes that produce resistance to 5 antibiotics. However, the rapid and point-of-care segment is expected to exhibit the fastest CAGR throughout the projected period. The rising demand for PoC and rapid diagnostics owing to their advantages such as short turnaround time, quick results, and affordable pricing. In addition, the robust product portfolio of rapid diagnostics and the surge in research activities to develop rapid diagnostic solutions are likely to fuel segment demand. For instance, in November 2021, researchers from Washington University developed a technique to detect AMR and provide results within 90 minutes.

Pathogen Insights

The methicillin resistant staphylococcus aureus was the leading sub-subsegment of the pathogen segment in 2021, accounting for a revenue share of 23.5%, and is expected to witness lucrative growth opportunities in coming years. The increasing incidences of MRSA across hospital settings are the vital factor responsible for segment expansion. For instance, according to the CDC, around 33% of the population have S. aureus on their nose without illness and around two in every 100 of these people get affected with MRSA.

Moreover, surge in regulatory approvals for diagnostic tests to detect MRSA is another factor contributing to the segment expansion. For instance, in January 2020, the U.S. FDA approved a novel diagnostic test on bacteriophage technology for the detection of MRSA. Moreover, in recent years, FDA has approved Cobas vivoDx MRSA diagnostic test for the quantification of MRSA.

Clostridium Difficile is expected to be the second-highest revenue contributor during the forecast period. The increased share is accounted for the high incidence rate and increasing capability of developing resistance against multiple drugs. C. difficile strains develop resistance to current antibiotics through multiple mechanisms, which include the acquisition of antibiotic resistance genes via altered expression of proteins, transfer of mobile genetic elements, gene mutations, iron metabolism, DNA repair, and via biofilm formation.         

End-user Insights

The high market of hospital segment dominated the market and accounted for a revenue share of 48.7% in 2021. This is attributed to the increasing incidence of hospital-acquired infections, surge in hospitalizations due to the high incidence of AMR infections, prolonged hospital stays, increasing access to novel diagnostic technologies, affordability, and improving healthcare coverage. Moreover, pathogenic infections such as MRSA, CDI, and DRSP are capable of causing bloodstream infections, sepsis, pneumonia, and surgical site infection. Thus, the high incidence of pathogen-oriented disorders in hospitals is also supporting segment growth. In addition, in April 2022, a study conducted by BD, Pfizer, and Merck found that more than 270 hospitals in the U.S. reported a surge in antimicrobial resistance during the COVID-19 pandemic.

Whereas the diagnostic laboratories segment is expected to grow at the fastest pace in the coming years. The increasing burden of infectious diseases and the technological advancements of laboratories are expected to drive segment growth. Moreover, affordable services and high penetration of laboratories that perform a number of diagnostic procedures are also anticipated to fuel market expansion. Laboratory testing can assist in patient treatment, quantify emerging threats, and provide accurate results for proper treatment. The CDC has launched its AR laboratory network for quick diagnosis of resistance and informing local authorities to combat the spread.

Regional Insights

In 2021, North America held the largest revenue share of 42.7% in 2021 in the antimicrobial resistance diagnostics market. The growth of the North America region is attributed to the high risk of developing antimicrobial resistance, supportive government policies to combat AMR and the presence of advanced healthcare infrastructure driving the region’s growth. Moreover, the presence of leading market players and Strategic initiatives undertaken by them is likely to fuel segment expansion in the coming years.

Asia Pacific is anticipated to be the fastest-growing region during the forecast period. The growth of the region is augmented by the presence of untapped market potential, high incidence rate of antibiotic resistance, and a surge in demand for cost-efficient diagnostic solutions are expected to facilitate region expansion. In addition, the large, targeted population and rising geriatric population in the region and various awareness programs by the government are also expected to spur the region’s growth. Furthermore, the increase the R&D activities related to the development of advanced diagnostic solutions is also expected to fuel region expansion.

Key Companies & Market Share Insights

Key market players are adopting strategies such as new product development, merger & acquisition, and partnership to increase their market share. For instance, in April 2022, bioMerieux announced an agreement to acquire Specific Diagnostics. This acquisition has strengthened its position in the global antimicrobial resistance diagnostics market. Some of the prominent players in the global antimicrobial resistance diagnostics market include:

• bioMerieux

• F. Hoffmann-La Roche Ltd.

• Abbott

• Hologic, Inc.

• BD

• Danaher

• Accelerate Diagnostics, Inc.

• Molsid

• Vela Diagnostics

• Visby Medical, Inc.

• OpGen 

Antimicrobial Resistance Diagnostics Market Report Scope

Global Antimicrobial Resistance Diagnostics Market Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For the purpose of this report, Grand View Research has segmented the global antimicrobial resistance diagnostics market report on the basis of technology, pathogen, end-user, and region:

• Technology Outlook (Revenue, USD Million, 2018 - 2030)

  • Microbiology Culture

  • Immunoassay

  • PCR

  • NGS

  • Mass Spectrometry

  • Rapid & Point of Care

  • Others

• Pathogen Outlook (Revenue, USD Million, 2018 - 2030)

  • Drug Resistant Streptococcus Pneumoniae (DRSP)

  • Drug Resistant Campylobacter (DRC)

  • Clostridium Difficile (CD)

  • Methicillin Resistant Staphylococcus Aureus (MRSA)

  • Drug Resistant Neisseria Gonorrhoeae (DRNG)

  • Drug Resistant Salmonella (DRNTS)

  • Others

• End-user Outlook (Revenue, USD Million, 2018 - 2030)

  • Hospitals

  • Diagnostic Laboratories

  • Pharmaceutical & Biotechnology Companies

  • Others

• Regional Outlook (Revenue, USD Million, 2018 - 2030)

  • North America

    • U.S.

    • Canada

  • Europe

    • U.K.

    • Germany

    • France

    • Italy

    • Spain

  • Asia Pacific

    • Japan

    • China

    • India

    • South Korea

    • Australia

  • Latin America

    • Brazil

    • Mexico

    • Argentina

  • Middle East & Africa

    • South Africa

    • Saudi Arabia

    • UAE